Extended Data Fig. 2: Lifetime risks of breast and ovarian cancer associated with categories of pathogenic and benign variants.
From: Functional evaluation and clinical classification of BRCA2 variants

A,B, Lifetime risk estimates for breast cancer (A) and ovarian cancer (B) associated with categories (P_Strong, P_Strong/Moderate/Supporting, B_Strong, B_Strong/Moderate/Supporting) of BRCA2 DNA binding domain SNVs from the BRCA2 MAVE study. Standards included known pathogenic (all protein truncating alterations), known benign (benign variants established by the ClinGen BRCA1/2 VCEP), general population breast/ovarian (age related risks of these cancers from the general SEER registry).